Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies by Schweizer, Anja et al.
© 2011 Schweizer et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Vascular Health and Risk Management 2011:7 49–57
Vascular Health and Risk Management Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
49
ORiginAL ReSeARcH
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/VHRM.S16925
Assessing the general safety and tolerability  
of vildagliptin: value of pooled analyses from  
a large safety database versus evaluation  
of individual studies
Anja Schweizer1
Sylvie Dejager2
James e Foley3
Wolfgang Kothny3
1novartis Pharma Ag, Basel, 
Switzerland; 2novartis Pharma SAS, 
Rueil-Malmaison, France; 3novartis 
Pharmaceuticals corporation, east 
Hanover, nJ, USA
correspondence: Anja Schweizer 
novartis Pharma Ag, Postfach,  
cH-4002 Basel, Switzerland  
Tel + 41 61 3243530  
Fax + 41 61 3247487  
email anja.schweizer@novartis.com
Aim: Analyzing safety aspects of a drug from individual studies can lead to difficult-to-interpret 
results. The aim of this paper is therefore to assess the general safety and tolerability, including 
incidences of the most common adverse events (AEs), of vildagliptin based on a large pooled 
database of Phase II and III clinical trials.
Methods: Safety data were pooled from 38 studies of $12 to $104 weeks’ duration. AE profiles 
of vildagliptin (50 mg bid; N = 6116) were evaluated relative to a pool of   comparators (placebo 
and active comparators; N = 6210). Absolute incidence rates were calculated for all AEs, serious 
AEs (SAEs), discontinuations due to AEs, and deaths.
Results: Overall AEs, SAEs, discontinuations due to AEs, and deaths were all reported with a 
similar frequency in patients receiving vildagliptin (69.1%, 8.9%, 5.7%, and 0.4%, respectively) 
and patients receiving comparators (69.0%, 9.0%, 6.4%, and 0.4%, respectively), whereas drug-
related AEs were seen with a lower frequency in vildagliptin-treated patients (15.7% vs 21.7% 
with comparators). The incidences of the most commonly reported specific AEs were also similar 
between vildagliptin and comparators, except for increased incidences of hypoglycemia, tremor, 
and hyperhidrosis in the comparator group related to the use of sulfonylureas.
Conclusions: The present pooled analysis shows that vildagliptin was overall well tolerated 
in clinical trials of up to .2 years in duration. The data further emphasize the value of a pooled 
analysis from a large safety database versus assessing safety and tolerability from individual 
studies.
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Introduction
Vildagliptin is an orally effective dipeptidyl peptidase-4 (DPP-4) inhibitor that has 
been studied in a large clinical program as monotherapy and combination therapy.1 
It binds covalently to the catalytic site of DPP-4, eliciting prolonged enzyme inhibition. 
This raises intact glucagon-like peptide-1(GLP-1) levels both after meal ingestion and 
in the fasting state. By increasing concentrations of active GLP-1, vildagliptin improves 
β- and α-cell sensitivity to glucose.2 This results in glucose-sensitive modulation of 
insulin and glucagon secretion, improving both fasting and postprandial glycemia, 
with a low risk for hypoglycemia and no weight gain.
Areas of potential safety concern related to type 2 diabetes (T2DM) itself 
(ie, cardiovascular and hepatic safety), as well as potential safety concerns specific 
to DPP-4 inhibitors (ie, immune system, skin, and pancreatitis), have been analyzed Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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previously for vildagliptin based on a large pooled database, 
with no increased risks identified versus comparators.3,4 
However, other safety aspects, such as general safety and 
tolerability, including incidences of most common specific 
adverse events (AEs), have so far been reviewed in the 
literature from individual studies only.1,5,6 Although this is 
often the only possible approach early in the development of 
a new drug, such data from single and often relatively small 
studies are less reliable than analyses from larger datasets. 
Furthermore, specific design features, study duration, sample 
size, and, in particular, the comparator chosen for individual 
studies can influence the AE reporting rates in a specific 
study, which needs to be weighed against the overall experi-
ence in a clinical trial program. For example, one issue that 
arose from an individual study with vildagliptin was related 
to edema. In contrast to other studies, Bolli et al,7 in a trial 
comparing vildagliptin and pioglitazone as add-on therapy 
with metformin, reported peripheral edema as the most com-
mon AE for vildagliptin with an incidence even somewhat 
higher than for the thiazolidinedione (TZD) itself.
Based on these considerations, it was of interest to assess 
the general safety and tolerability of vildagliptin, as well as 
the specific risk of edema-related AEs with vildagliptin treat-
ment, using the previously described large pooled database 
of vildagliptin Phase II and III clinical studies.4 We report 
here the results of these new pooled safety analyses.
Methods
Populations
The safety analyses are based on the previously reported 
pool of 38 Phase II and Phase III studies that used vilda-
gliptin as monotherapy or in combination with metformin, 
TZDs, sulfonylureas (SUs), or insulin for $12 weeks up 
to $104 weeks.4
For the analysis of overall AEs, AEs by system organ 
class (SOC) or preferred term (PT), serious AEs (SAEs), 
discontinuations due to AEs, and deaths, as well as edema-
related AEs, the “all studies (excluding open-label) safety 
population”, which excludes open-label studies in order to 
minimize reporting bias, was used. Supplementary Table 1 
briefly describes each of the studies included in this pooled 
dataset.
Peto odds ratios (ORs) were additionally calculated for 
edema-related AEs, as a single study had previously reported 
a higher incidence with vildagliptin.7 Calculation of ORs 
requires a comparator; thus, calculation of ORs and the   resulting 
Forest plot for edema-related AEs used data pooled from all 
controlled studies excluding open-label trials. This   population 
is termed “all controlled studies (excluding open-label) safety 
  population” (see Supplementary Table 1 for details).
In addition to being analyzed in the all studies (exclud-
ing open-label) safety population, confirmed hypoglycemic 
episodes (as defined in this article) were also assessed 
in monotherapy (monotherapy [excluding open-label] 
safety population), which was deemed more appropriate 
considering that the risk of hypoglycemia is influenced by 
antidiabetic background therapy. Confirmed hypoglycemia 
is thus not reflected under the most common AEs in the all 
studies (excluding open-label) safety population in Table 1. 
The monotherapy (excluding open-label) safety population 
includes 21 studies (see Supplementary Table 1 for details 
on the contributing studies).
Assessments
All AEs were recorded and assessed by the investigator as to 
the severity and possible relationship to the study   medication. 
This included laboratory abnormalities if   considered 
an AE by the investigator. All laboratory   assessments 
were performed by central laboratories (for details, see 
  Ligueros-Saylan et al4).
Confirmed hypoglycemia was defined as symptoms 
  suggestive of low blood glucose confirmed by self-monitored 
blood glucose measurement ,3.1 mmol/L plasma glucose 
equivalent.
Standardization of terms
AEs were encoded in all studies using the Medical Dictionary 
for Regulatory Activities (MedDRA, Version 12.1) system. 
This is a medically validated terminology database developed 
by the International Conference on Harmonization. Within the 
MedDRA, AEs are grouped by SOC, eg, “cardiac   disorders” 
or “gastrointestinal disorders”. Within an SOC, specific AEs 
are identified by PT. The PTs included in the analysis of 
edema-related AEs are allergic edema, generalized edema, 
local swelling, localized edema, edema, peripheral edema, 
pitting edema, skin edema, skin swelling, and swelling.
Data analysis
For AEs, SAEs, discontinuations due to AEs, and deaths, inci-
dences were calculated as number of patients with an event 
divided by the number of patients in the treatment group. 
For edema-related AEs (as defined previously), exposure-
adjusted incidences were additionally calculated as number of 
patients having events per 100 subject-year exposure (SYE), 
defined as 100×(number of patients with an event divided by 
the total exposure time in years).Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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To further compare edema-related AEs between vilda-
gliptin and comparators, for each trial, Peto OR and the 
corresponding 95% confidence interval (CI) were calculated. 
The pooled estimate was obtained using a fixed-effect model 
and presented in a forest plot. An OR below unity is indica-
tive of a treatment effect favoring vildagliptin. Correction 
for continuity using the inverse of the opposite arm size was 
used when zero events occurred.8 This correction causes less 
bias than the standard continuity correction of 0.5 when the 
sizes of the treatment arms are unbalanced.9
Safety data of vildagliptin 50 mg bid (the highest 
approved and most commonly used dosage of the drug) are 
reported along with pooled safety data of all comparators 
(active or placebo) from the safety populations.
ethics and good clinical practice
All study participants provided written informed consent. 
All protocols were approved by the independent ethics 
  committee/institutional review board at each study site or 
country. All studies were conducted using good clinical prac-
tice and in accordance with the Declaration of Helsinki.
Results
exposure and demography
As detailed in Ligueros-Saylan et al,4 in the all studies 
(excluding open-label) safety population, 6116 patients 
received vildagliptin 50 mg bid (representing 7313.6 SYE) 
and 6210 patients received any comparator (representing 
6512.7 SYE). The comparators group included placebo 
(23.7%), SUs (41.7%), metformin (18.8%), TZDs (12.3%), 
and acarbose (3.5%).
The mean duration of exposure was 62.4 weeks with 
vildagliptin 50 mg bid and 54.7 weeks with comparators 
(Table 1). This allows for direct comparisons between 
the two groups and provides a conservative estimate, as the 
slightly longer exposure with vildagliptin tends to favor the 
comparator group.
The demographic and baseline characteristics of patients 
in the all studies (excluding open-label) safety population 
have also been described previously.4 In brief, the popu-
lation studied was representative of a broad spectrum of 
T2DM patients, with a mean age, body mass index, glyco-
sylated hemoglobin A, fasting plasma glucose, and duration 
of T2DM of approximately 56 years, 31.4 kg/m2, 8.1%, 
9.8 mmol/L, and .4 years, respectively, and with nearly 
one-third of patients having some degree of renal insuf-
ficiency (glomerular filtration rate [Modification of Diet in 
Renal Disease] #80 mL/min per 1.73 m2).
Overall safety and tolerability
Tables 1 and 2 report AE profiles for vildagliptin 50 mg bid 
and comparators in the all studies (excluding open-label) 
safety population.
Overall AEs, SAEs, discontinuations due to AEs, and 
deaths were all reported with a similar frequency in patients 
receiving vildagliptin (69.1%, 8.9%, 5.7%, and 0.4%, 
  respectively) and patients receiving comparators (69.0%, 
9.0%, 6.4%, and 0.4%, respectively), and drug-related AEs 
were seen with a lower frequency in vildagliptin-treated 
patients (15.7% vs 21.7% with comparators) (Table 1).
When the reported AEs were analyzed by SOC 
(Table 2), the incidences with vildagliptin and comparators 
were also similar overall. The four SOCs with the highest 
incidence of AEs were infections and infestations (35.3% 
for   vildagliptin vs 32.4% for comparators), gastrointes-
tinal disorders (23.5% vs 22.4%), musculoskeletal and 
Table 1 Adverse event (Ae) summary and most common Aes 
(all studies [excluding open-label] safety population)
n (%) Vildagliptin   
50 mg bid
Comparatorsa
N = 6116 N = 6210
Mean exposure (weeks) 62.4 54.7
AEs 4225 (69.1) 4228 (69.0)
Drug-related AEs 961 (15.7) 1349 (21.7)
Serious AEs 545 (8.9) 557 (9.0)
Discontinuations due to AEsb 347 (5.7) 400 (6.4)
Deaths 24 (0.4) 23 (0.4)
Most common AEs  
(occurring in $3% of patients  
in either group): 
  nasopharyngitis 577 (9.4) 528 (8.5)
  Headache 431 (7.0) 371 (6.0)
  Dizziness 390 (6.4) 460 (7.4)
  Back pain 356 (5.8) 321 (5.2)
  Diarrhea 345 (5.6) 418 (6.7)
    Upper respiratory  
tract infection
317 (5.2) 254 (4.1)
  Bronchitis 297 (4.9) 278 (4.5)
  Hypertension 297 (4.9) 315 (5.1)
  Influenza 290 (4.7) 282 (4.5)
  Arthralgia 289 (4.7) 236 (3.8)
  nausea 247 (4.0) 268 (4.3)
  Pain in extremity 217 (3.5) 238 (3.8)
  Fatigue 210 (3.4) 253 (4.1)
  cough 206 (3.4) 210 (3.4)
  Urinary tract infection 204 (3.3) 185 (3.0)
  Asthenia 198 (3.2) 306 (4.9)
  Tremor 184 (3.0) 471 (7.6)
  edema peripheral 180 (2.9) 219 (3.5)
  Hyperhidrosis 169 (2.8) 422 (6.8)
Notes: acomparators = placebo plus active comparators; bOnly Aes that caused the 
study drug to be permanently discontinued are included.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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c  onnective tissue disorders (22.5% vs 21.1%), and nervous 
system disorders (21.6% vs 23.7%). Of note, there were 
no imbalances between vildagliptin and comparators in 
the overall reporting rates under the cardiac (6.1% with 
  vildagliptin vs 6.0% with comparators), hepatobiliary 
(1.7% vs 1.6%), skin (12.6% vs 14.4%), and vascular (7.8% 
in both groups) SOCs. The most notable difference was 
observed in the metabolism/nutrition SOC, with incidences 
of 7.8% for vildagliptin and 11.4% for comparators, which 
were mainly due to hypoglycemia.
Overall, there were no appreciable trends in SAEs 
reported, and the majority of SAEs were scattered across 
many different SOCs. The primary SOC with the highest 
incidence of SAEs was cardiac disorders, with no imbalance 
between vildagliptin (1.7%) and comparators (1.9%). The 
only other SOCs with an incidence of SAEs $ 1% were 
infections and infestations (1.5% with vildagliptin 50 mg 
bid vs 1.4% with comparators); benign, malignant, and 
unspecified neoplasms (including cysts and polyps) (1.2% 
vs 1.1%); nervous system disorders (1.1% vs 1.0%); and 
gastrointestinal disorders (1.0% vs 0.9%).
There were no meaningful imbalances across the treat-
ment groups in the incidence of AEs leading to discontinu-
ation in any SOC. The SOC with the highest incidence of 
AEs leading to discontinuation was gastrointestinal disorders 
(1.2% with vildagliptin vs 1.4% with comparators).
A summary of the most commonly ($3% in either 
group) reported specific AEs for vildagliptin 50 mg 
bid and comparators is also provided in Table 1. All of 
the individual AEs were reported with a low frequency 
of ,10%. The most common AEs across treatment groups 
were nasopharyngitis (9.4% with vildagliptin vs 8.5% with 
comparators), dizziness (6.4% vs 7.4%), headache (7.0% 
vs 6.0%), and diarrhea (5.6% vs 6.7%). The incidences 
of the most commonly reported AEs were overall similar 
between vildagliptin and comparators. The most notable 
differences were lower incidences with vildagliptin of 
tremor (3.0% vs 7.6%) and hyperhidrosis (2.8% vs 6.8%). 
Furthermore, confirmed hypoglycemia was reported less 
frequently with vildagliptin (1.7%) than with compara-
tors (5.8%). Hypoglycemia was additionally assessed in a 
pooled monotherapy population, which was deemed more 
appropriate than the assessment in the overall pooled data-
set, considering that the risk of hypoglycemia is influenced 
by antidiabetic background therapy. In the pooled mono-
therapy safety population, confirmed hypoglycemic events 
were reported in 0.5% of patients treated with vildagliptin 
versus 0.3% treated with placebo and 0.6% treated with 
all comparators (the comparator group consisted of 38.3% 
metformin, 20.7% placebo, 17.9% SU, 7.2% acarbose, and 
15.9% TZD).
edema
As depicted in Figure 1, there was no evidence of an increased 
risk of edema-related AEs with vildagliptin 50 mg bid relative 
to comparators. The Peto OR for vildagliptin 50 mg bid was 
0.72 (95% CI 0.59–0.88), indicating a statistically significant 
risk reduction versus the comparator group.
Table 2 Adverse events (Aes) by system organ class (SOc) (all 
studies [excluding open-label] safety population)
n (%) Vildagliptin  
50 mg bid
Comparatorsa
N = 6116 N = 6210
Mean exposure (weeks) 62.4 54.7
AEs by SOC:
    Blood and lymphatic  
system disorders
125 (2.0) 114 (1.8)
    cardiac disorders 375 (6.1) 375 (6.0)
    congenital, familial,  
and genetic disorders
12 (0.2) 13 (0.2)
    ear and labyrinth disorders 189 (3.1) 221 (3.6)
    endocrine disorders 40 (0.7) 32 (0.5)
    eye disorders 368 (6.0) 356 (5.7)
    gastrointestinal disorders 1440 (23.5) 1393 (22.4)
    general disorders/administration  
site conditions
884 (14.5) 1069 (17.2)
    Hepatobiliary disorders 102 (1.7) 99 (1.6)
    immune system disorders 63 (1.0) 63 (1.0)
    infections and infestations 2162 (35.3) 2014 (32.4)
    injury, poisoning, and  
procedural complications
595 (9.7) 522 (8.4)
    investigations 368 (6.0) 427 (6.9)
    Metabolism and nutrition  
disorders
476 (7.8) 706 (11.4)
    Musculoskeletal and  
connective tissue disorders
1374 (22.5) 1313 (21.1)
    Benign, malignant, and  
unspecified neoplasms
149 (2.4) 144 (2.3)
    nervous system disorders 1320 (21.6) 1474 (23.7)
    Pregnancy, puerperium and  
perinatal conditions
2 (0.0) 8 (0.1)
    Psychiatric disorders 480 (7.8) 474 (7.6)
    Renal and urinary disorders 291 (4.8) 255 (4.1)
    Reproductive system and  
breast disorders
241 (3.9) 220 (3.5)
    Respiratory, thoracic and  
mediastinal disorders
601 (9.8) 570 (9.2)
    Skin and subcutaneous  
tissue disorders
769 (12.6) 893 (14.4)
    Social circumstances 12 (0.2) 3 (0.0)
    Surgical and medical procedures 18 (0.3) 11 (0.2)
    Vascular disorders 475 (7.8) 484 (7.8)
Note: acomparators = placebo plus active comparators.Vascular Health and Risk Management 2011:7
Vilda 50 mg bid
n/N (%)
189/6116 (3.09) 211/4872 (4.33)
Comparators
n/N (%)
0.72 (0.59–0.88)
0.01 0.1 11 0
Vilda better Vilda worse
100
Peto OR (95% Cl)
Figure 1 incidences and Peto odds ratio (OR) for edema-related adverse events with vildagliptin 50 mg bid versus comparators (placebo and active comparators) in the all 
controlled studies (excluding open-label) safety population.
Abbreviation:   Vilda, vildagliptin
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The overall incidence of any edema-related AE was 
low in both treatment groups (Table 3). The unadjusted and 
  SYE-adjusted incidences of any edema-related AEs were 
lower for vildagliptin than for comparators (Table 1). The most 
commonly reported edema-related AE was peripheral edema, 
and for this AE the incidence was also lower with   vildagliptin 
(2.9%, 2.46 events per 100 SYE) than with comparators 
(3.5%, 3.36 events per 100 SYE). For all other specific edema-
related AEs, the SYE-adjusted incidences with vildagliptin 
were the same as or lower than with comparators.
Discussion
The present paper has evaluated in a large pooled database 
safety aspects of the DPP-4 inhibitor vildagliptin that were 
previously assessed only from individual study results. 
Although the latter approach   represents generally a good 
approach to judging the efficacy of a drug, it has considerable 
limitations when assessing safety and tolerability and can 
lead to difficult-to-interpret or even   misleading results. On 
the one hand, sample sizes of individual trials are often too 
small to reliably assess whether any imbalances observed in 
individual AEs reflect a true excess over the comparator treat-
ment studied or rather a chance finding. On the other hand, 
the study duration, the safety surveillance measures, and, in 
particular, the comparator chosen for individual studies can 
influence the AE reporting rates in a specific study. Another 
complication arises if the results of an individual study are 
extrapolated as being representative for the overall safety of 
a drug, as happens in the literature, especially if pooled data 
are not available.
For vildagliptin, a higher incidence of peripheral edema, 
for example, was observed in a study that compared the drug 
with the TZD pioglitazone, for which edema is a known side 
effect.7 In contrast, the new pooled analysis presented here 
did not confirm an increased incidence of edema-related 
events with vildagliptin but rather showed a statistically 
significant risk reduction versus the comparator group 
(OR = 0.72). Peripheral edema specifically occurred at an 
incidence rate of 2.46 events per 100 SYE with vildagliptin 
50 mg bid versus 3.36 events per 100 SYE with compara-
tors. Of note, only 12% of patients in the comparator group 
were treated with TZDs. Another study reported an imbal-
ance with vildagliptin versus comparator treatment for the 
AE of hypertension.10 In contrast, hypertension was well 
balanced when analyzed in the large pooled dataset (4.9% 
with vildagliptin vs 5.1% with comparators). These examples 
clearly highlight the value and importance of pooled safety 
analyses.
Table  3  edema-related  adverse  events  (Aes)  (all  studies 
[excluding open-label] safety population)
Vildagliptin  
50 mg bid
Comparatorsa
N = 6116 N = 6210
n (%) 
Subject-year exposure adjusted
Any edema-related AE 198 (3.2) 242 (3.9)
2.71 3.72
  generalized edema 2 (0.0) 2 (0.0)
0.03 0.03
  Local swelling 1 (0.0) 1 (0.0)
0.01 0.02
  edema 10 (0.2) 9 (0.1)
0.14 0.14
  Peripheral edema 180 (2.9) 219 (3.5)
2.46 3.36
  Pitting edema 9 (0.1) 12 (0.2)
0.12 0.18
  Skin swelling 0 (0.0) 1 (0.0)
0.00 0.02
Note: acomparators = placebo plus active comparators.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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The safety of vildagliptin versus all comparators was 
previously assessed with regard to organs, systems, or tis-
sues of particular interest in T2DM and areas of potential 
concern with DPP-4 inhibitors.4 The meta-analyses indicated 
that vildagliptin was not associated with an increased risk 
of hepatic events or hepatic enzyme elevations indicative of 
drug-induced liver injury, pancreatitis, skin-related toxicity, 
or infections. In line with these results, the data presented 
here did not show any imbalances between vildagliptin and 
comparators for AEs in the SOCs of hepatobiliary disorders, 
skin and subcutaneous tissue disorders and infection and 
infestations.
The present pooled analysis further shows a general 
safety profile of vildagliptin 50 mg bid in clinical trials of 
up to .2 years in duration that was very similar to that of 
comparators regarding the overall incidences of AEs, SAEs, 
discontinuations due to AEs, and deaths. This also holds true 
when AEs were analyzed by SOCs or the most common 
AEs were evaluated. The only notable differences were for 
confirmed hypoglycemia and the likely hypoglycemia-related 
AEs of tremor and hyperhidrosis, for which lower incidences 
were observed with vildagliptin than with comparator treat-
ment, mainly due to the use of SUs as a comparator in sev-
eral studies (representing .40% of the comparator group). 
Because hypoglycemia incidences are largely influenced by 
antidiabetic background therapy, it is important to review 
hypoglycemia rates for specific treatment regimens. The 
overall safety population used for the present safety analyses 
consists of a broad range of studies with different treatment 
regimens, including add-on to insulin; thus, the frequency 
of confirmed hypoglycemia was also assessed in a pooled 
monotherapy safety population. Of the patients treated with 
vildagliptin monotherapy, 0.5% reported confirmed hypo-
glycemic episodes, which is very similar to the rate found 
with placebo (0.3%).
Taken together, the present pooled analysis provides a 
more comprehensive and reliable assessment of the general 
safety and tolerability of vildagliptin than can be obtained by 
extracting safety data from individual studies only.
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Table S1 Vildagliptin studies contributing to safety analyses
Study  
no.
Study description Phase/ 
population
Randomized  
patients*
Treatment  
duration**
Publication***
Monotherapy
1 Placebo-controlled dose-ranging study in drug-naïve  
T2DM patients (HbA1c 6.8%–10%)
ii/a,b,c 279 12 weeks 1
2 Uncontrolled 40-week extension to Study 1 ii/a,c 141 52 weeks not available
3 Placebo-controlled low-dose efficacy/safety study in  
drug-naïve T2DM patients (HbA1c 6.8%–11%)
ii/a,b,c 100 12 weeks 2
4 Placebo-controlled dose-ranging study (efficacy/safety) in  
drug-naïve T2DM patients (HbA1c 7.5%–10%)
iii/a,b,c 632 24 weeks 3
5 Uncontrolled 28-week extension to Study 4 iii/a,c 440 52 weeks ncT00138541
6 Placebo-controlled long-term efficacy/safety study in drug-naïve  
T2DM patients with mild hyperglycemia (HbA1c 6.2%–7.5%)
iii/a,b,c 306 52 weeks 4,5
7 Placebo-controlled 52-week extension to Study 6 iii/a,b,c 131 104 weeks 6
8 Active-controlled (metformin) long-term efficacy/safety  
study in drug-naïve T2DM patients (HbA1c 7.5%–11%)
iii/a,b,c 780 52 weeks 7
9 Active-controlled (metformin) 52-week extension to Study 8 iii/a,b,c 463 104 weeks 8
10 Active-controlled (gliclazide) long-term efficacy/safety study in  
drug-naïve T2DM patients (HbA1c 7.5%–11%)
iii/a,b,c 1092 104 weeks 9
11 Active-controlled (acarbose) efficacy/safety study in  
drug-naïve T2DM patients (HbA1c 7.5%–11%)
iii/a,b,c 661 24 weeks 10
12 Active-controlled (rosiglitazone) efficacy/safety study  
in drug-naïve T2DM patients (HbA1c 7.5%–11%)
iii/a,b,c 786 24 weeks 11
13 Active-controlled (rosiglitazone) 80-week extension to Study 12 iii/a,b,c 598 104 weeks 12
14 Active-controlled (pioglitazone) dose regimen comparison  
study in drug-naïve T2DM patients (HbA1c 9%–11%)
iii/a,b,c 273 12 weeks ncT00101673
15 Placebo-controlled efficacy/safety study in patients with IGT iii/a,b,c 179 12 weeks 13
16 Placebo-controlled mechanistic study (β-cell function) in drug-naïve 
T2DM patients with mild hyperglycemia (HbA1c # 7.5%)
iii/a,b,c 89 52 weeks ncT00260156
17 Placebo-controlled dose-ranging study (efficacy/safety)  
in drug-naïve T2DM patients (HbA1c 7.5%–10%)
iii/a,b,c 354 24 weeks 14
18 Active-controlled (metformin) efficacy/safety study in  
drug-naïve elderly ($65 years) T2DM patients (HbA1c 7%–9%)
iii/a,b,c 335 24 weeks 15
Combination therapy with metformin
19 Placebo-controlled dose-selection study in patients  
inadequately controlled by metformin (HbA1c 7.0%–9.5%)
ii/a,b 132 12 weeks 16
20 Placebo-controlled 40-week extension to Study 19 ii/a,b 71 52 weeks 16
21 Placebo-controlled efficacy/safety study in T2DM patients  
inadequately controlled with metformin (HbA1c 7.5%–11%)
iii/a,b 544 24 weeks 17
22 Uncontrolled 28-week extension to Study 21 iii/a  417 52 weeks ncT00138515
23 Active-controlled (glimepiride) long-term efficacy/safety study  
in T2DM patients treated with metformin (HbA1c . 6.5%–8.5%)
iii/a,b 3118 $104 weeks 18,19
24 Active-controlled (gliclazide) long-term efficacy/safety study  
in T2DM patients inadequately controlled with metformin  
(HbA1c 7.5%–11%)
iii/a,b 1007 52 weeks 20
25 Active-controlled (pioglitazone) long-term efficacy/safety study  
in T2DM patients inadequately controlled with metformin  
(HbA1c 7.5%–11%)
iii/a,b 576 52 weeks 21,22
26 Placebo-controlled efficacy/safety study in T2DM patients  
inadequately controlled with metformin (HbA1c 7.5%–11%)  
to compare a.m. vs p.m. dosing regimens
iii/a,b 370 24 weeks 23
27 Efficacy/safety study in T2DM patients treated with metformin  
(HbA1c 6.5%–9%) to compare vildagliptin as add-on to  
metformin vs uptitration of metformin 
iii/a,b,c**** 914 24 weeks 24
28 Efficacy/safety study of initial fixed combination therapy  
of vildagliptin and metformin in drug-naïve  
T2DM patients (HbA1c 7.5%–11%)
iii/a,b,c**** 1179 24 weeks 25
(Continued)
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Table S1 (Continued)
Study  
no.
Study description Phase/ 
population
Randomized  
patients*
Treatment  
duration**
Publication***
Combination therapy with TZD
29 Placebo-controlled efficacy/safety study in T2DM patients  
inadequately controlled by TZD (HbA1c 7.5%–11%)
iii/a,b 463 24 weeks 26
30 Uncontrolled 28-week extension to Study 29 iii/a 312 52 weeks ncT00138554
31 Initial combination (vildagliptin/pioglitazone) efficacy/safety study  
in drug-naïve T2DM patients (HbA1c 7.5%–11%)
iii/a,b,c**** 607 24 weeks 27
Combination therapy with SU
32 Placebo-controlled efficacy/safety study in T2DM patients  
inadequately controlled by SU (HbA1c 7.5%–11%)
iii/a,b 515 24 weeks 28
33 Uncontrolled 28-week extension to Study 32 iii/a 332 52 weeks ncT00138580
Combination therapy with insulin
34 Placebo-controlled efficacy/safety study in T2DM patients  
treated with insulin (HbA1c 7.5%–11%)
iii/a,b 296 24 weeks 29
35 Uncontrolled 28-week extension to Study 34 iii/a 200 52 weeks 30
Notes: *For extension studies: patients who entered extension; **For extension studies: duration of core + extension study. ***ClinicalTrials.gov identifier number is 
provided if data are not yet published; ****Monotherapy arms only. Population a = all studies (excluding open-label) safety population. Population b = all controlled studies 
(excluding open-label) safety population; Population c = monotherapy (excluding open-label) safety population.
Abbreviations: HbA1c, glycosylated hemoglobin A; igT, impaired glucose tolerance; SU, sulfonylurea; T2DM, type 2 diabetes; TZD, thiazolidinedione.
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